STOCK TITAN
  1. Home
  2. News
  3. NXGL

NexGel, Inc - NXGL STOCK NEWS

Welcome to our dedicated page for NexGel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on NexGel stock.

NexGel, Inc (symbol: NXGL) specializes in the manufacture of advanced hydrogel solutions. The company's core business revolves around creating unique trans-dermal delivery systems initially developed and FDA-approved for the hospital wound care market. Today, NexGel has expanded its offerings to include consumer over-the-counter (OTC) products, prescription (Rx) applications, medical devices, and cosmetic products.

NexGel Inc is renowned for its high water content, electron beam cross-linked, aqueous polymer hydrogels. These gels are integral to various applications such as wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company's expertise lies in producing custom gels utilizing proprietary manufacturing technologies. The hydrogels and consumer products are created through a combination of proprietary and non-proprietary mixing, coating, and cross-linking technologies.

The company's recent achievements and current projects highlight its ongoing commitment to innovation and excellence in the hydrogel market. NexGel continually explores new partnerships and collaborations to enhance its product offerings and market reach.

For investors and stakeholders, it is important to note the company's strategic communications are managed by KCSA, with Valter Pinto serving as the Managing Director. NexGel’s financial condition and market performance are presented through regular updates, ensuring transparency and keeping investors well-informed.

For the latest developments, financial updates, and detailed information about NexGel, Inc, please refer to the following contact details:
Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications
Phone: 212.896.1254
Email: valter@kcsa.com

News

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

Rhea-AI Summary
NEXGEL, Inc. reported a record year in 2023 with nearly 100% revenue growth driven by branded products and contract manufacturing. The company expanded its operational infrastructure, secured key partnerships, and made strategic investments for future growth. Financially, revenue for 2023 was $4.1 million, a 99.7% increase from 2022, with gross profit margin improving to 15.2%. Despite revenue growth, cost of revenues and selling, general, and administrative expenses also increased. NEXGEL ended 2023 with a net loss of $3.2 million but had $2.7 million in cash. The company expects first quarter revenue of $1.25 million, excluding a non-refundable deposit from AbbVie. Overall, NEXGEL is positioning itself for significant growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.95%
Tags
none
-
News

NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday

Rhea-AI Summary
NEXGEL, Inc. reschedules its financial results conference call for the fourth quarter and full year 2023 to Monday, April 1st at 8:30 a.m. ET due to the Good Friday holiday closure. CEO Adam Levy aims to enhance visibility and convenience for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
earnings
-
News

NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th

Rhea-AI Summary
NEXGEL, Inc. will report its financial results for Q4 and full year 2023 on March 28, 2024. The Company specializes in medical and OTC products, including hydrogels. A conference call will follow the release of financial results at 4:30 P.M. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences earnings
News

NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th

Rhea-AI Summary
NEXGEL, Inc. announced that CEO Adam Levy will present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th, 2024. NEXGEL is a prominent provider of medical and OTC products, specializing in hydrogels for healthcare and consumer use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.53%
Tags
conferences
-
News

NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders

Rhea-AI Summary
NEXGEL, Inc. announces a registered direct offering of common stock and warrants, raising approximately $975,000 for additional working capital. Insiders, including management and the Board of Directors, participated in the offering to support the company's growth opportunities. The offering is facilitated by Alere Financial Partners, LLC, and is made under the Company's shelf registration statement on Form S-3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.83%
Tags
offering
-
News

NEXGEL to Present at The Microcap Conference, January 30th through February 1st

Rhea-AI Summary
NEXGEL, Inc. announced that its CEO will be participating in The Microcap Conference from January 30th to February 1st. The company will present on January 31st and February 1st, and management will be available for 1x1 meetings. Interested parties can register to attend and schedule meetings via email.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
conferences
News

NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024

Rhea-AI Summary
NEXGEL, Inc. (NASDAQ: NXGL) announces a 12,000 square foot expansion of its CG Converting and Packaging facility in Granbury, Texas to support expected growth in product demand from new strategic partnerships and its own branded products. The expansion is funded by the landlord and will be completed in the second quarter of 2024. The company is purchasing new automation equipment to support the growth in product demand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
-
News

NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America

Rhea-AI Summary
NEXGEL, Inc. (NASDAQ: NXGL) partners with STADA Arzneimittel AG to distribute and commercialize consumer health OTC products in North America in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
partnership
-
News

NEXGEL Acquires Kenkoderm Psoriasis Skincare Line

Rhea-AI Summary
NEXGEL, Inc. (NASDAQ: NXGL) acquires Kenkoderm, a skincare product company focusing on treating Psoriasis symptoms. Kenkoderm is profitable and expected to boost NEXGEL's revenue and margins. The acquisition aims to optimize marketing and supply chain operations for further growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
acquisition
News

NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year

Rhea-AI Summary
NEXGEL, Inc. (NASDAQ: NXGL) Announces Record Revenue and Improved Gross Profit Margin in Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
earnings

FAQ

What is the current stock price of NexGel (NXGL)?

The current stock price of NexGel (NXGL) is $4.73 as of December 20, 2024.

What is the market cap of NexGel (NXGL)?

The market cap of NexGel (NXGL) is approximately 32.5M.

What does NexGel, Inc specialize in?

NexGel, Inc specializes in manufacturing advanced hydrogel solutions used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

What are the primary applications of NexGel's products?

NexGel's hydrogels are used for wound care, medical diagnostics, transdermal drug delivery, and in cosmetics.

What is unique about NexGel's manufacturing technology?

NexGel uses proprietary and non-proprietary mixing, coating, and cross-linking technologies to create high water content, electron beam cross-linked polymer hydrogels.

Who handles investor relations for NexGel?

Investor relations for NexGel are managed by Valter Pinto, the Managing Director at KCSA Strategic Communications.

How did NexGel begin its journey in the hydrogel market?

NexGel began by developing FDA-approved trans-dermal delivery systems for the hospital wound care market.

What is the significance of NexGel’s hydrogels in consumer products?

NexGel's hydrogels are significant in consumer products for their applications in over-the-counter medications, prescription drugs, medical devices, and cosmetics.

How can one stay updated with NexGel's latest news and developments?

You can stay updated with NexGel's latest news and developments by contacting Valter Pinto at KCSA Strategic Communications or following company announcements.

What financial information is available for NexGel investors?

NexGel provides regular financial updates and detailed reports through their investor relations managed by KCSA, ensuring transparency for their stakeholders.

Where can I find more detailed information about NexGel, Inc?

For more detailed information about NexGel, Inc, you can reach out to their investor contact, Valter Pinto, at KCSA Strategic Communications.

Stock NXGL logo
NexGel, Inc

Nasdaq:NXGL

NXGL Rankings

#5094 Ranked by Market Cap
N/A Ranked by Dividends

NXGL Stock Data

32.49M
5.28M
20.09%
2.95%
0.4%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
LANGHORNE